Kypha Revenue and Competitors
Estimated Revenue & Valuation
- Kypha's estimated annual revenue is currently $8M per year.
- Kypha's estimated revenue per employee is $251,000
Employee Data
- Kypha has 32 Employees.
- Kypha grew their employee count by 0% last year.
Kypha's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Senior Scientist | Reveal Email/Phone |
Kypha Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.1M | 49 | -18% | $10M | N/A |
#2 | $30.4M | 121 | 29% | N/A | N/A |
#3 | $139.8M | 913 | -3% | $200K | N/A |
#4 | $84.1M | 0 | N/A | $1.2M | N/A |
#5 | $43.4M | 173 | 30% | N/A | N/A |
#6 | $64.5M | 257 | 12% | N/A | N/A |
#7 | $64.3M | 205 | 26% | $129.6M | N/A |
#8 | $19.6M | 78 | -7% | N/A | N/A |
#9 | $65.8M | 262 | 7% | N/A | N/A |
#10 | $73.7M | 235 | 20% | $115.5M | N/A |
What Is Kypha?
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing. RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications. Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
keywords:N/A
N/A
Total Funding
32
Number of Employees
$8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Dublin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.1M | 32 | -9% | N/A |
#2 | $5.5M | 32 | 45% | N/A |
#3 | $4.2M | 32 | 28% | N/A |
#4 | $3.7M | 32 | 7% | N/A |
#5 | $4.5M | 32 | 19% | N/A |